# Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

> **NCT07290569** · PHASE2 · RECRUITING · sponsor: **Oruka Therapeutics, Inc.** · enrollment: 160 (estimated)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** ORKA-001
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07290569
- **Lead sponsor:** Oruka Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-03
- **Primary completion:** 2027-06
- **Final completion:** 2028-12
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07290569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07290569, "Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07290569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*